BlackRock’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $33.6M | Buy |
8,069,373
+560,302
| +7% | +$2.36M | ﹤0.01% | 2920 |
|
|
2026
Q1 | $31.2M | Sell |
7,509,071
-266,331
| -3% | -$1.08M | ﹤0.01% | 2800 |
|
|
2025
Q4 | $50.2M | Buy |
7,775,402
+1,249,719
| +19% | +$7.79M | ﹤0.01% | 2513 |
|
|
2025
Q3 | $36.5M | Buy |
6,525,683
+49,077
| +0.8% | +$212K | ﹤0.01% | 2712 |
|
|
2025
Q2 | $21.4M | Buy |
6,476,606
+540,852
| +9% | +$1.55M | ﹤0.01% | 2981 |
|
|
2025
Q1 | $17.2M | Sell |
5,935,754
-62,844
| -1% | -$190K | ﹤0.01% | 3028 |
|
|
2024
Q4 | $21.4M | Buy |
5,998,598
+175,521
| +3% | +$809K | ﹤0.01% | 3015 |
|
|
2024
Q3 | $29M | Buy |
5,823,077
+368,334
| +7% | +$1.43M | ﹤0.01% | 2803 |
|
|
2024
Q2 | $14.2M | Buy |
5,454,743
+4,109,867
| +306% | +$13.7M | ﹤0.01% | 3174 |
|
|
2024
Q1 | $5.73M | Buy |
1,344,876
+866,857
| +181% | +$2.89M | ﹤0.01% | 3613 |
|
|
2023
Q4 | $966K | Sell |
478,019
-1,949
| -0.4% | -$3.44K | ﹤0.01% | 4267 |
|
|
2023
Q3 | $734K | Buy |
479,968
+73,666
| +18% | +$127K | ﹤0.01% | 4326 |
|
|
2023
Q2 | $670K | Buy |
406,302
+46,644
| +13% | +$84.4K | ﹤0.01% | 4402 |
|
|
2023
Q1 | $410K | Buy |
359,658
+1,943
| +0.5% | +$1.68K | ﹤0.01% | 4577 |
|
|
2022
Q4 | $323K | Sell |
357,715
-16,163
| -4% | -$15.2K | ﹤0.01% | 4722 |
|
|
2022
Q3 | $437K | Buy |
373,878
+2,162
| +0.6% | +$2.44K | ﹤0.01% | 4761 |
|
|
2022
Q2 | $237K | Sell |
371,716
-4,801
| -1% | -$6.39K | ﹤0.01% | 4993 |
|
|
2022
Q1 | $983K | Buy |
376,517
+28,151
| +8% | +$82.2K | ﹤0.01% | 4670 |
|
|
2021
Q4 | $1.35M | Buy |
348,366
+17,420
| +5% | +$87.4K | ﹤0.01% | 4561 |
|
|
2021
Q3 | $1.44M | Sell |
330,946
-20,068
| -6% | -$78.7K | ﹤0.01% | 4447 |
|
|
2021
Q2 | $1.39M | Sell |
351,014
-1,005,386
| -74% | -$4.02M | ﹤0.01% | 4413 |
|
|
2021
Q1 | $7.05M | Buy |
1,356,400
+50,562
| +4% | +$269K | ﹤0.01% | 3776 |
|
|
2020
Q4 | $6.99M | Buy |
1,305,838
+35,764
| +3% | +$214K | ﹤0.01% | 3551 |
|
|
2020
Q3 | $6.17M | Sell |
1,270,074
-155,732
| -11% | -$1.02M | ﹤0.01% | 3481 |
|
|
2020
Q2 | $6.93M | Buy |
1,425,806
+1,214,344
| +574% | +$5.59M | ﹤0.01% | 3388 |
|
|
2020
Q1 | $463K | Buy |
211,462
+7,217
| +4% | +$27.4K | ﹤0.01% | 4074 |
|
|
2019
Q4 | $1.19M | Sell |
204,245
-166,473
| -45% | -$866K | ﹤0.01% | 3953 |
|
|
2019
Q3 | $1.18M | Sell |
370,718
-10,953
| -3% | -$41K | ﹤0.01% | 3919 |
|
|
2019
Q2 | $1.6M | Sell |
381,671
-420,085
| -52% | -$2.15M | ﹤0.01% | 3853 |
|
|
2019
Q1 | $5.54M | Buy |
801,756
+159,956
| +25% | +$1.12M | ﹤0.01% | 3369 |
|
|
2018
Q4 | $4.04M | Buy |
641,800
+170,396
| +36% | +$2.15M | ﹤0.01% | 3462 |
|
|
2018
Q3 | $8.25M | Buy |
+471,404
| New | +$7.77M | ﹤0.01% | 3322 |
|
Other funds holding AQST
BCM
RI
SB
SCM
PBM
BlackRock's AQST Position: Q2 2026 in Review
BlackRock increased its Aquestive Therapeutics (AQST) stake by 7.5% in Q2 2026, buying an estimated $2.36M and bringing the position to 8,069,373 shares worth $33.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2920.
BlackRock first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $50.2M in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.
- BlackRock held 8,069,373 shares of Aquestive Therapeutics worth $33.6M as of Q2 2026.
- BlackRock bought 560,302 Aquestive Therapeutics shares in Q2 2026, an estimated $2.36M.
- Aquestive Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2920 holding.
- BlackRock first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
- BlackRock's Aquestive Therapeutics position peaked at $50.2M in Q4 2025.
- 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.